NCT06823401View on ClinicalTrials.gov

Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)

RecruitingOBSERVATIONAL

Enrollment

270

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

March 10, 2025

Study Completion Date

December 31, 2025

Conditions

NSCLC

Trial Locations (2)

000144

ENROLLING_BY_INVITATION

Istituto Tumori Regina Elena, Roma

00128

RECRUITING

Istituto Tumori Regina Elena, Roma

All Listed Sponsors

lead

Fondazione Ricerca Traslazionale

OTHER